Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors

Bioorg Med Chem Lett. 2022 Nov 15:76:128991. doi: 10.1016/j.bmcl.2022.128991. Epub 2022 Sep 18.

Abstract

Cyclin-dependent kinases play an important role in the regulation of cell cycle and transcription. Selective CDK4/6 inhibitors have been demonstrated to be effective in the treatment of cancer. In this article, we described the design and synthesis of a series of pteridine-7(8H)-one derivatives as dual CDK4/6 inhibitors. Among them, the most promising compound L2 exhibited significant inhibitory activity against CDK4 and CDK6 with IC50 values of 16.7 nM and 30.5 nM respectively and showed excellent selectivity to CDK1/2/7/9. Moreover, compound L2 displayed potent antiproliferative activities at low digital micromolar range via inducing apoptosis in breast and colon cancer cells. In all, we developed a new series of pteridine-7(8H)-one derivatives which exhibited promising antitumor activities as selective CDK4/6 inhibitors.

Keywords: CDK4/6 inhibitors; Scaffold hopping; Structure-activity relationships.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Apoptosis
  • Cell Cycle
  • Cell Line, Tumor
  • Cell Proliferation
  • Cyclin-Dependent Kinase 4 / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Pteridines* / pharmacology
  • Structure-Activity Relationship

Substances

  • Pteridines
  • Cyclin-Dependent Kinase 4
  • Protein Kinase Inhibitors
  • Antineoplastic Agents